Trazodone--a new assay procedure and some pharmacokinetic parameters.
1 A simple and specific procedure is described for the determination of the new anti-depressant trazodone in human plasma utilising reverse-phase HPLC which is sensitive to 20 ng ml-1. 2 Following oral administration of single 50 mg doses of two formulations of trazodone on separate occasions to healthy fasted volunteers, the peak plasma concentration, time to peak concentration, area under the curve, elimination rate constant and half-life were determined. 3 The two formulations are closely similar and they are considered to have comparable bioavailability.
D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D006801:Humans; D007700:Kinetics; D010879:Piperazines / Q000032:analysis*; D014196:Trazodone / Q000032:analysis* / Q000378:metabolism
D010879:Piperazines; D014196:Trazodone